Current Atherosclerosis Reports

, Volume 11, Issue 5, pp 371–376 | Cite as

Lessons learned from the ONTARGET and TRANSCEND trials



Cardiovascular disease (CVD) accounts for one of every three deaths in the United States. In recent years, a greater understanding of the renin-angiotensin-aldosterone system’s (RAAS) contribution to CVD, particularly in the area of blood pressure regulation, has emerged. Thus, interrupting or blocking the RAAS has become a key component in the treatment of hypertension and other cardiovascular conditions. The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing CVD in high-risk populations has been demonstrated by two recently completed major trials: the Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial (ONTARGET) and the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND). This article describes these key studies and their outcomes and identifies critical issues that they raise for clinical practice in terms of choosing the most effective therapy for patients with existing CVD.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21–e181.PubMedCrossRefGoogle Scholar
  2. 2.
    Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001, 103:904–912.PubMedGoogle Scholar
  3. 3.
    Candido R, Louise BM, Jandeleit-D, et al.: Vasoactive peptides and the kidney. In Brenner & Rector’s The Kidney. Edited by Brenner BM, Levine SA. Philadelphia: Saunders Elsevier; 2008.Google Scholar
  4. 4.
    Atlas SA: The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007, 13:9–20.PubMedGoogle Scholar
  5. 5.
    Barreras A, Gurk-Turner C: Angiotensin II receptor blockers. Proc Baylor Univ Med Center 2003, 16:123–126.Google Scholar
  6. 6.
    Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234–242.PubMedGoogle Scholar
  7. 7.
    Task Force Members, Lopez-Sendon J, Swedberg K, et al.: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: the Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004, 25:1454–1470.PubMedCrossRefGoogle Scholar
  8. 8.
    Mancia G, De Backer G, Dominiczak A, et al.: ESH/ESC 2007 guidelines for the management of arterial hypertension. Rev Esp Cardiol 2007, 60:968.e961–e994.CrossRefGoogle Scholar
  9. 9.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  10. 10.
    Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.PubMedCrossRefGoogle Scholar
  11. 11.
    Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.PubMedCrossRefGoogle Scholar
  12. 12.
    Malmqvist K, Kahan T, Edner M, et al.: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001, 19:1167–1176.PubMedCrossRefGoogle Scholar
  13. 13.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.PubMedCrossRefGoogle Scholar
  14. 14.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  16. 16.
    Maggioni AP, Anand I, Gottlieb SO, et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414–1421.PubMedCrossRefGoogle Scholar
  17. 17.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771PubMedCrossRefGoogle Scholar
  18. 18.
    The Ontarget Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefGoogle Scholar
  19. 19.
    Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553.PubMedCrossRefGoogle Scholar
  20. 20.
    TRANSCEND Investigators, Yusuf S, Teo K, et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174–1183.PubMedCrossRefGoogle Scholar
  21. 21.
    Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261–2266.PubMedCrossRefGoogle Scholar
  22. 22.
    Ripley TL, Harrison D: The power to TRANSCEND. Lancet 2008, 372:1128–1130.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Ralph H. Johnson VA Medical CenterMedical University of South CarolinaCharlestonUSA

Personalised recommendations